id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2026-C-3071-0001,FDA,FDA-2026-C-3071,"Filing of Color Additive Petition: International Association of Color Manufacturers; Request to Amend the Color Additive Regulations to Remove the Solvents Methylene Chloride, Trichloroethylene, and Ethylene Dichloride",Proposed Rule,Petition,2026-04-01,2026,4,2026-04-01,2026-06-02,2026-04-01 17:16:12,2026-06295,1,0,09000064b9249960
FDA-2026-N-2590-0001,FDA,FDA-2026-N-2590,Microbiology Devices; Reclassification of Mycobacterium Tuberculosis Cell-Mediated Immunity Tests and Immune Response Enzyme-Linked Immunospot Tests,Proposed Rule,Request for Comment,2026-03-30,2026,3,2026-03-30,2026-05-30,2026-04-13 09:00:30,2026-06064,1,0,09000064b92437b6
FDA-2025-N-5996-0001,FDA,FDA-2025-N-5996,Medical Devices; Radiology Devices; Classification of Blood Irradiators,Proposed Rule,Notice of Proposed Rulemaking (NPRM),2026-03-18,2026,3,2026-03-18,2026-05-19,2026-03-29 09:00:14,2026-05320,1,0,09000064b92216a5
FDA-2025-N-5995-0001,FDA,FDA-2025-N-5995,Effective Date of Requirement for Premarket Approval Applications for Blood Irradiators Intended To Prevent Metastasis,Proposed Rule,Notice of Proposed Rulemaking (NPRM),2026-03-18,2026,3,2026-03-18,2026-05-19,2026-03-21 09:00:16,2026-05322,1,0,09000064b92215cb